XML 44 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2023
Income Taxes  
Schedule of Gross Deferred Tax Asset and Related Valuation Allowance

    

2023

    

2022

 

Deferred income tax assets:

Net operating loss carryforward

$

88,746,869

$

82,784,742

Research and orphan drug credits

 

53,152,849

 

51,184,585

Capitalized research costs

 

10,748,355

 

7,125,276

Capitalized start-up costs

 

532,931

 

726,724

Patent amortization

 

42,541

 

58,010

Stock-based compensation

 

7,324,617

 

7,247,715

Accrued bonus

704,974

733,235

Operating lease liabilities

222,452

252,777

Other

87,097

210,237

Gross deferred income tax assets

 

161,562,685

 

150,323,301

Valuation allowance

 

(161,351,398)

 

(149,972,514)

Net deferred income tax assets

 

211,287

 

350,787

Deferred income tax liabilities:

Operating lease right-of-use assets

 

(211,287)

 

(206,704)

Property and equipment

 

 

(144,083)

Gross deferred income tax liabilities

 

(211,287)

 

(350,787)

Net deferred income tax asset/(liability)

$

$

Schedule of Reconciliations Between Statutory Federal Income Tax Rate and Effective Income Tax Rate of Income Tax Expense

    

2023

    

2022

    

2021

 

U.S. Federal statutory tax rate

 

21.0

%  

21.0

%  

21.0

%

State taxes

 

6.3

 

6.1

 

5.9

Research credit

 

0.7

 

0.6

 

0.9

Orphan drug credit

 

4.1

 

4.8

 

6.6

Other

(1.3)

(3.9)

(0.3)

Change in valuation allowance

 

(30.8)

 

(28.6)

 

(34.1)

Provision for income taxes

 

%

%

%